CC-BY-NC-ND 4.0 · Amer J Perinatol 2018; 35(02): 192-200
DOI: 10.1055/s-0037-1606352
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The 2014–2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States

Amanda M. Kong1, Leonard R. Krilov2, Jaime Fergie3, Mitchell Goldstein4, David Diakun1, Sally W. Wade5, Melissa Pavilack6, Kimmie K. McLaurin6
  • 1Watson Health Value Based Care, Truven Health Analytics, an IBM Company, Cambridge, Massachusetts
  • 2Pediatric Infectious Diseases, Children's Medical Center, NYU Winthrop, Mineola, New York
  • 3Department of Pediatric Infectious Disease, Driscoll Children's Hospital, Corpus Christi, Texas
  • 4Division of Neonatal Medicine, Loma Linda University Children's Hospital, Linda Loma, California
  • 5Wade Outcomes Research and Consulting, Salt Lake City, Utah
  • 6Health Economics and Outcomes Research, AstraZeneca, Gaithersburg, Maryland
Further Information

Publication History

06 June 2017

26 July 2017

Publication Date:
07 September 2017 (eFirst)


Objective This article aims to compare respiratory syncytial virus (RSV) immunoprophylaxis (IP) use and RSV hospitalization rates (RSVH) in preterm and full-term infants without chronic lung disease of prematurity or congenital heart disease before and after the recommendation against RSV IP use in preterm infants born at 29 to 34 weeks' gestational age (wGA).

Study Design Infants in commercial and Medicaid claims databases were followed from birth through first year to assess RSV IP and RSVH, as a function of infant's age and wGA. RSV IP was based on pharmacy or outpatient medical claims for palivizumab. RSVH was based on inpatient medical claims with a diagnosis of RSV.

Results Commercial and Medicaid infants 29 to 34 wGA represented 2.9 to 3.5% of all births. RSV IP use in infants 29 to 34 wGA decreased 62 to 95% (p < 0.01) in the 2014–2015 season relative to the 2013–2014 season. Compared with the 2013–2014 season, RSVH increased by 2.7-fold (p = 0.02) and 1.4-fold (p = 0.03) for infants aged <3 months and 29 to 34 wGA in the 2014–2015 season with commercial and Medicaid insurance, respectively. In the 2014–2015 season, RSVH for infants 29 to 34 wGA were two to seven times higher than full-term infants without high-risk conditions.

Conclusion Following the 2014 RSV IP guidance change, RSV IP use declined and RSVH increased among infants born at 29 to 34 wGA and aged <3 months.


This work was presented as a poster titled “Impact of 2014 American Academy of Pediatrics Guidance for RSV Immunoprophylaxis” at AMCP Nexus 2016, National Harbor, MD, October 3–6, 2016, and was presented as a platform presentation titled “Impact of 2014 American Academy of Pediatrics Policy for Respiratory Syncytial Virus (RSV) Immunoprophylaxis” at the Pediatric Academic Societies (PAS) 2017 Meeting, San Francisco, CA, May 6–9, 2017.